Invivo Therapeutics Holdings Corp  

(Public, NASDAQ:NVIV)   Watch this stock  
Find more results for OTC:NVIV
-0.15 (-3.03%)
Dec 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.80 - 5.00
52 week 3.50 - 10.36
Open 4.95
Vol / Avg. 150,740.00/192,962.00
Mkt cap 149.10M
P/E     -
Div/yield     -
EPS -0.76
Shares 32.03M
Beta 2.76
Inst. own 24%
Mar 2, 2017
Q4 2016 InVivo Therapeutics Holdings Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 4, 2016
Q3 2016 InVivo Therapeutics Holdings Corp Earnings Release
Sep 13, 2016
InVivo Therapeutics Holdings Corp at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -59.89% -173.13%
Return on average equity -70.55% -291.63%
Employees 30 -
CDP Score - -


1 Kendall Sq Fl 4
CAMBRIDGE, MA 02139-1562
United States - Map
+1-617-8635524 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Officers and directors

Mark D. Perrin Chairman of the Board, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Steven F. McAllister Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Tamara L. Joseph J.D. Senior Vice President, Chief Compliance Officer, General Counsel
Age: 52
Bio & Compensation  - Reuters
Thomas R. Ulich M.D. Chief Scientific Officer
Age: 61
Bio & Compensation  - Reuters
Lorianne K. Masuoka M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Pamela J. Stahl Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Ann Merrifield Lead Independent Director
Age: 65
Bio & Compensation  - Reuters
Jeffrey S. Hatfield Director
Bio & Compensation  - Reuters
Christina T. Morrison Director
Age: 48
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Independent Director
Age: 57
Bio & Compensation  - Reuters